AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced new indicative data from the ongoing clinical phase I MAD study with ACD856 showing that the substance reaches the brain, the target organ for the substance which is developed as a treatment for Alzheimer's disease.
ACD856, which is the company's leading drug candidate in the NeuroRestore platform, is currently undergoing a clinical phase I MAD study (Multiple Ascending Dose). The purpose of the study is to evaluate safety and tolerability after repeated dosing of different doses of the substance, but also to study the concentration of the substance in the body. AlzeCure has now received key data showing that ACD856 reaches the brain in relevant concentrations, something that supports the further development program for the drug candidate as oral treatment of, among other things, Alzheimer's disease.
“With these positive data showing that NeuroRestore ACD856 effectively crosses the blood-brain barrier and reaches the brain in high and relevant concentrations, we can move on to the next step – a signal detection study where the aim is to study early effect signals,” said Martin Jönsson, CEO of AlzeCure Pharma. This project has been fully developed by AlzeCure, from molecule to clinical studies, and shows the organization's ability, breadth and capacity,” continues Martin Jönsson.
ACD856 and the other substances in the NeuroRestore platform stimulate several important signaling systems in the brain, which can lead to improved cognition. Preclinical studies have shown that AlzeCure drug candidates strengthen the communication between nerve cells and improve cognitive ability including learning and memory functions.
